Amgen Inc. (AMG BE) stock market data APIs
€238.2349
0(0%)
as of June 30, 2025
Try our APIs with
free plan!
Amgen Inc. Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for AMG.BE.
Prev. Close
238.2349
Open
238.2349
High
238.2349
Low
238.2349
52 wk Range
227.6542-301.6786
Market Cap
105 182 M
Dividends (Yield)
0.0224
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amgen Inc. data using free add-ons & libraries
Get Amgen Inc. Fundamental Data
Amgen Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amgen Inc. News
New
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism. Continue Reading View Comments
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 202...
Jim Cramer Says That Amgen’s Stock “Did Not Deserve to Get Hit This Hard”
Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTid...
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Amgen AMGN is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the booming weight loss drug market. The obesity market is expected to expand t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
